NAMS Stock Forecast & Price Target

NewAmsterdam Pharma Co is viewed positively because obicetrapib addresses a large unmet need in lipid management, where as many as 50% of U.S. patients on cholesterol-lowering therapy do not reach target cholesterol goals and 9–15% cannot tolerate statins, while injectables remain costly and inconvenient. The drug has repeatedly shown meaningful LDL reductions of about 40% in phase II studies, with a clean safety profile, no food effect, and QD oral dosing that could support broad adoption as an add-on or switch therapy in a multi-$B market. The bullish case is further supported by a 9,500-patient outcomes trial with 30 months of follow-up that is believed to be >90% powered for a 20% MACE reduction, alongside revenue potential estimated at $1.6B in U.S. sales and $3.1B worldwide.

NewAmsterdam Pharma Co is viewed negatively because its core asset, obicetrapib, remains highly dependent on proving that LDL-C lowering translates into meaningful MACE reduction, while HORIZON has increased uncertainty around any extra benefit from Lp(a) lowering. The company also faces major execution and financing risk as a small biotech with no revenues, possible dilution, and a 2027 composition-of-matter patent expiry that could weaken long-term exclusivity in a crowded, highly genericized market. Even if clinical data remain supportive, commercialization may be difficult against existing branded therapies, payer pressure, and the possibility that prior CETP inhibitor failures, safety issues, or inconclusive trials prevent the stock from supporting upside beyond cash-like downside risk.